Rybelsus 3 mg is an innovative oral hypoglycemic medication belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. The drug is indicated to improve glycemic control in adults with type 2 diabetes mellitus. The active substance is Semaglutide at a dosage of 3 mg. The drug stimulates insulin secretion when blood glucose levels are high, suppresses glucagon release, delays gastric emptying, and reduces appetite, thereby assisting in weight management.
Manufacturer: Novo Nordisk A/S (Denmark). A global leader in diabetes care and development, ensuring the highest standards of quality and cutting-edge biotechnology in endocrinology.
Key Advantages and Features of Rybelsus 3 mg:
- ✅ Oral GLP-1 Formulation: The first and only tablet form of semaglutide, providing an effective alternative to injectable counterparts.
- ✅ Effective Glycemic Control: Significantly reduces glycated hemoglobin (HbA1c) and fasting plasma glucose levels.
- ✅ Weight Management Support: Promotes natural appetite reduction and weight loss in patients with type 2 diabetes.
- ✅ High Novo Nordisk Quality: Guarantees original Danish manufacturing, advanced research, and rigorous quality control.